Paper Details
- Home
- Paper Details
RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
Author: AbbateAntonio, BeutlerAnna, BrucatoAntonio, ChangSteven, CremerPaul, FangFang, GervaisAnais, ImazioMassimo, KleinAllan L, LeWinterMartin, LinDavid, MartiniAlberto, PaoliniJohn F, PerrinRandy
Original Abstract of the Article :
Recurrent pericarditis (RP) occurs in 15% to 30% of patients following a first episode, despite standard treatment with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids; many patients become dependent on corticosteroids. Rilonacept (KPL-914), an interleukin-1α and β inhibitor, i...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.ahj.2020.07.004
データ提供:米国国立医学図書館(NLM)
Rilonacept: A New Hope for Recurrent Pericarditis
Recurrent pericarditis, an inflammation of the heart sac, is a frustrating condition that can leave patients feeling like a trapped camel in a sandstorm. Current treatments can provide relief, but many patients require long-term medication. This study explores the potential of rilonacept, a new drug targeting inflammation, as a treatment for recurrent pericarditis.
Rilonacept: A Promising New Approach
The researchers designed a large-scale clinical trial (RHAPSODY) to assess the effectiveness and safety of rilonacept in patients with recurrent pericarditis. The trial's primary outcome measure is the time to pericarditis recurrence. Secondary outcomes include symptom severity and overall well-being.
Hope for a Brighter Future
This study offers hope for a better future for patients struggling with recurrent pericarditis. If rilonacept proves to be effective and safe, it could provide a much-needed solution for those seeking long-term relief from this debilitating condition.
Dr.Camel's Conclusion
Recurrent pericarditis can be a real challenge, and this research offers a glimmer of hope for a more effective treatment. Rilonacept, with its targeted approach to inflammation, could be a game-changer for patients seeking lasting relief. As a researcher, I am eager to see the results of this study and the potential impact it could have on improving the lives of those affected by this condition.
Date :
- Date Completed 2020-10-08
- Date Revised 2020-10-08
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.